# OpACIN (NCT02437279)

> Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02437279
- Phase: PHASE1
- Status: UNKNOWN
- Sponsor: The Netherlands Cancer Institute
- Conditions: Stage III Skin Melanoma
- Interventions: Surgery of the tumor; Infusion with ipilimumab 3 mg/kg q3wks; Infusion with nivolumab 1 mg/kg q3wks
- Enrollment: 20
- Primary outcome: The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
- Primary outcome: Safety as measured by SUSARs.
- Primary outcome: The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood
- Primary outcome: Feasibility as measured adherence to the timelines in the study protocol.

## Commentary we found

- Podcasts: 6
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=opacin-nct02437279